Diagnostic Accreditation Program

ACCREDITATION STANDARDS

Mammography

Copyright © 2024 by the Diagnostic Accreditation Program and the College of Physicians and Surgeons of British Columbia.

All rights reserved. No part of this publication may be used, reproduced or transmitted, in any form or by any means electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system or any nature, without the prior written permission of the copyright holder, application for which shall be made to:

Diagnostic Accreditation Program
College of Physicians and Surgeons of British Columbia
300–669 Howe Street
Vancouver BC V6C 0B4

The Diagnostic Accreditation Program and the College of Physicians and Surgeons of BC has used their best efforts in preparing this publication. As websites are constantly changing, some of the website addresses in this publication may have moved or no longer exist.

Introduction

In addition to the general standards, the discipline-specific standards for mammography provides additional mandatory requirements and best practices.

Interventional mammography – standards navigation

Interventional mammography procedure type	No.

Patient preparation

No.		Description	Risk	Reference	Change
					Revised
MA2.0		MAMMOGRAPHY PATIENT PREPARATION *Guidance: See also global modality GM2.0 for additional requirements.*			
MA2.2		Pre-examination information is collected and assessed prior to commencing the examination. *Guidance: See also global modality GM2.2.*			
MA2.2.3	M	The patient's breast surgical history is documented, which includes any history of breast protheses, breast reductions, needle and surgical breast biopsies, mastectomies, partial mastectomies and any other relevant breast surgical information. *Guidance: The patient is screened for breast protheses prior to the examination, as excessive compression could damage or rupture the prothesis.*	M	Mammo-AC-23	Revised
MA2.2.4	M	The patient's breast health concern or clinical breast symptom is documented. *Guidance: The location of palpable breast symptoms is described according to various conventions including the clock face position, distance from the nipple, breast quadrant and or location within the coronal plane.*	M	Mammo-AC-23	New
MA2.2.5	M	The patient's recent hormonal medication use is documented (e.g. estrogen).	M	Mammo-AC-23	

No.		Description	Risk	Reference	Change
MA3.3.4	M	Breast health concerns and clinical breast symptoms are marked using radiopaque devices, in accordance with facility protocol. *Guidance: Radiopaque devices may be used to identify a patient's breast health concern and clinical breast symptoms (i.e. non-cyclical pain, palpable mass, skin abnormalities, etc.) and to help correlate them with ultrasound findings. It is recommended that all radiopaque devices*			

Interpretation and reports

No.		Description	Risk	Reference	Change
					Revised
MA8.0		MAMMOGRAPHY INTERPRETATION AND REPORTS *Guidance: See also global modality GM8.0 for additional requirements.*			
MA8.5		Reports are comprehensive and include appropriate patient and relevant clinical information. *Guidance: See GM8.2 for additional requirements.*			New
MA8.5.1	M	Reports include a succinct description of the overall breast density using ACR BI-RADS® breast density descriptors. *Guidance: For a list of ACR BI-RADS® descriptors review the ACR BIRADS Atlas 5th edition (*			

No.	Description	Risk	Reference	Change

No.		Description	Risk	Reference	Change
MA12.2.16	M	Acceptance testing of digital mammography systems includes evaluation of the automatic exposure control (AEC) performance.	H	SC-36	Revised
MA12.2.18	M	Acceptance testing of digital mammography systems includes evaluation of the backup timer.	H	Mammo-AC-23	Revised
MA12.2.19	M	Acceptance testing of digital mammography systems includes an evaluation of the dosimetry (mean glandular dose).	H	SC-36	Revised
MA12.2.21	M	Acceptance testing of digital mammography systems includes evaluation of image spatial resolution. *Guidance: Modular transfer function (MTF) is recommended when applicable.*	H	SC-36	Revised
MA12.2.22	M	Acceptance testing of digital mammography systems includes an evaluation of image contrast.	H	Mammo-AC-23	Revised
MA12.2.23	M	Acceptance testing of digital mammography systems includes evaluation of image quality using a MAP- or ACR-approved breast mimicking QC Phantom.	H	ACR-Mammo-QC	Revised
MA12.2.24	M	Acceptance testing of digital mammography systems includes evaluation of the digital detector residual image (e.g. ghosting).	H	SC-36	Revised
MA12.2.25	M	Acceptance testing of digital mammography systems includes evaluation of the image geometric distortion.	H	SC-36	Revised
MA12.2.27	M	Acceptance testing of digital mammography systems includes an assessment of misseW*nBT/F1 84t of			

No.		Description	Risk	Reference	Change
MA12.3.1	M	Acceptance testing of digital breast tomosynthesis systems is performed according to MA12.2.	H	Mammo-AC-23	New
MA12.3.2	B	Acceptance testing of digital breast tomosynthesis systems includes evaluation of Z resolution, to ensure blurring in the z-direction is not excessive.		ACR-QC- Mammo	New
MA12.3.3	B	Acceptance testing of digital breast tomosynthesis systems includes evaluation of volume coverage, to ensure the entire breast volume is imaged.		ACR-QC-Mammo	New
MA12.4		Acceptance testing of stereotactic biopsy guidance equipment is performed after purchase and prior to clinical use. *Guidance: See DES2.1 for additional requirements.*			New
MA12.4.1	M	Acceptance testing of stereotactic biopsy guidance equipment is performed as per manufacturer's specifications or industry accepted best practices.	M	Mammo-AC-23	New
MA12.4.2	M	Acceptance testing of stereotactic biopsy guidance equipment includes an assessment of needle localization accuracy.	M	ACR-QC- Stereo	New

Quality assurance

No.	Description	Risk	Reference	Change

No.		Description	Risk	Reference	Change
MA13.10.5	M	Weekly quality control testing of digital mammography and digital breast tomosynthesis systems includes evaluation of artifacts using a uniform phantom covering the entire detector for all target and filter combinations used (i.e. flat field or full field artifact testing). *Guidance: An artifact is considered significant if it may mimic or obscure anatomic features.*	M	CARMAP-Std	New
MA13.10.6	M	Weekly quality control testing of digital mammography and digital breast tomosynthesis systems includes evaluation of artifacts using a uniform phantom covering the entire magnification stand for all target filter combinations used.	M	CARMAP-Std	New
MA13.10.7	B	Weekly quality control testing of digital mammography and digital breast tomosynthesis systems includes evaluation of the contrast-to-noise ratio (CNR).		CARMAP-Std	New

No.		Description	Risk	Reference	Change
MA13.12.2	M	Records are retained of every rejected image, including the reason the image was rejected (e.g. insufficient image quality, patient motion, artifacts, X-ray equipment failure, etc.).	M	Mammo-AC-23	New
MA13.12.3	M	Quarterly quality control testing of digital mammography and digital breast			

Stereotactic biopsy guidance equipment quality assurance

No.		Description	Risk	Reference	Change
MA13.16		Routine quality control procedures are established and used to monitor performance of stereotactic biopsy guidance equipment.			New
MA13.16.1	M	Routine quality control testing of stereotactic biopsy guidance equipment is performed as per manufacturer's specifications or industry-accepted best practices.	M	Mammo-AC-23	New
MA13.16.2	M	Annual quality control testing of stereotactic biopsy guidance equipment includes an assessment of needle localization accuracy.	M	ACR-QC-Stereo	New

American College of Radiology; 1999. Av90nf1 0 0 1 72 529.35 Tm0 gtB0.000011802 0 792 612 reW*nBT4f(199omBT/F58.2 31.5 129.5 3BT/Sp